Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative…

Overview of attention for article published in Blood, November 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 26 news outlets

blogs: 2 blogs

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 48 news stories from 26 outlets.

Atara Biotherapeutics' Ebvallo Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

MarketScreener, 20 Dec 2022

(Nasdaq: ATRA) and Pierre Fabre today announced that the (EC) has granted marketing authorization for Ebvallo (tabelecleucel…

Atara Biotherapeutics' Ebvallo® (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

Crwe World, 20 Dec 2022

Only Approved Therapy for EU Patients with Rare and Potentially Deadly Cancer Facing Median Survival of Only a Few Months…

Ebvallo® (Tabelecleucel) von Atara Biotherapeutics erhält die Zulassung der Europäischen Kommission [...]

Aktien Check, 19 Dec 2022

Thousand Oaks, Kalif. und Castres, Frankreich (ots/PRNewswire) - Die einzige zugelassene Therapie für EU-Patienten, die an…

Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

Spoke, 19 Dec 2022

THOUSAND OAKS, Calif.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 44 additional news stories.